Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Presidium of China's annual legislative session holds 2nd meeting
Chinese Women's Health, Education Continue to Improve
(CPC Congress) 20th CPC National Congress Concludes
Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
China to Create New Opportunities for the World with Its Own Development: Xi
Xi Sends Congratulatory Letter to Global Observance of World Cities Day 2022
Standing Committee of Political Bureau of CPC Central Committee Discusses Optimizing COVID
LeBron James UNFOLLOWS Diddy on Instagram after video of assault on ex
Xi Meets Senegalese President Sall
Colton Herta shows speed as Honda fights back in penultimate Indy 500 practice session
China's used vehicle sales up in first 2 months